Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

Hopital Erasme, Brussels

Prince of Wales Hospital, Randwick

Western Health (Sunshine Hospitals), St Albans

Monash Medical Centre, Moorabbin, Bentleigh East

St. John of God Subiaco Hospital, Subiaco

St John of God Murdoch Hospital, Murdoch

SUNY Upstate Medical University, Syracuse

University of Rochester, Rochester

Thomas Jefferson University, Sydney Kimmel Cancer Center, Philadelphia

Hospital General Universitario Gregorio Marafi6n, Madrid

Hospital Universitario de Fuenlabrada, Fuenlabrada

Hospital Universitario de Fuenlabrada, Madrid

Lynn Cancer Institute, Boca Raton

Cleveland Clinic, Cleveland

University of Michigan, Ann Arbor

Hospital Universitario Miguel Servet, Zaragoza

University of Iowa Hospitals and Clinics, Iowa City

University of Kansas Cancer Center, Westwood

Ochsner Clinic Foundation, New Orleans

Baylor College of Medicine, Houston

Joe Arrington Cancer Research Treatment Center, Lubbock

Rocky Mountain Cancer Centers, Denver

Huntsman Cancer Institute at The University of Utah, Salt Lake City

Banner MD Anderson Cancer Center, Gilbert

City of Hope, Duarte

Providence Saint Joseph Medical Center, Burbank

Scripps Cancer Center, La Jolla

Soulhern California Permanente Medical Group, San Marcos

Kaiser Permanente Medical Center, Vallejo

University of California, Davis Comprehensive Cancer Center, Sacramento

Kaiser Permanente NW Oncology Research, Portland

Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, Lebanon

Tom Baker Cancer Centre, Calgary

British Columbia Cancer Agency, Vancouver

QEII Health Sciences Centre, Halifax

London Regional Cancer Program, London

Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto

Princess Margaret Hospital, Toronto

St Josephs Health Centre, Toronto

Hospital Universitari Germans Trias i Pujol - lnstituto Catalan d'Oncologia (!CO), Barcelona

Bristol Haematology & Oncology Centre, Bristol

Sarah Cannon Research Institute UK, London